Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 01, 2020 08:30 ET | Source: Jounce Therapeutics, Inc.

Gilead Sciences and Jounce Therapeutics Announce Exclusive License Agreement for Novel Immunotherapy Program

– Gilead Will Have Exclusive Rights to Develop and Commercialize Anti-CCR8 Antibody – – Gilead to Make $85 Million Upfront Payment and $35 Million Equity Investment – FOSTER CITY, Calif. and...